Der var ingen forskel i forekomsten af endometriekarcinom og endometriehyperplasi mellem Fablyn - og placebobehandlede kvinder.
There was no difference between FABLYN- and placebo-treated women in the incidences of endometrial carcinoma and endometrial hyperplasia.